Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862074 | 0.99 | MCHR1 (0.73) | MCHR1GAAKCNQ2OPRK1HPGD | |
| SCHEMBL5862836 | 0.93 | MCHR1 (0.82) | MCHR1GAAKCNQ2OPRK1MEN1 | |
| SCHEMBL5862031 | 0.85 | MCHR1 (1.00) | MCHR1OPRK1SMN1; SMN2 | |
| SCHEMBL5862827 | 0.84 | MCHR1 (0.98) | MCHR1OPRK1SMN1; SMN2 | |
| SCHEMBL5862204 | 0.83 | MCHR1 (0.63) | MCHR1GAAPOLBMEN1KMT2A | |
| SCHEMBL6069427 | 0.80 | MCHR1 (0.74) | MCHR1GAAKCNQ2 | |
| SCHEMBL5862138 | 0.76 | MCHR1 (0.82) | MCHR1MEN1KMT2A | |
| SCHEMBL5860926 | 0.75 | MCHR1 (0.81) | MCHR1MEN1KMT2A | |
| SCHEMBL5862173 | 0.75 | MCHR1 (0.59) | MCHR1HPGDPOLBMEN1KMT2A | |
| SCHEMBL5861242 | 0.74 | MCHR1 (0.58) | MCHR1HPGDPOLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | claimed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | claimed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885GAA 381/4885KCNQ2 1546/4885 |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885GAA 381/4885KCNQ2 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.